Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England.
The UK was the first country to use meningococcal serogroup C conjugate (MCC) vaccines, which were licensed on the basis of immunogenicity and safety data but without a formal efficacy study. Increased surveillance during the first 9 months since introduction has shown that short-term efficacy of the MCC vaccine in England was 97% (95% CI 77-99) for teenagers and 92% (65-98) for toddlers. These early results confirm the superiority of MCC over plain C polysaccharide vaccines, which are ineffective in young children.
Ramsay
M E
ME
Andrews
N
N
Kaczmarski
E B
EB
Miller
E
E
D000293:Adolescent; D004739:England; D006801:Humans; D017589:Immunization Programs; D007223:Infant; D008589:Meningococcal Infections / Q000517:prevention & control*; D022401:Meningococcal Vaccines; D016896:Treatment Outcome; D018074:Vaccines, Conjugate
D022401:Meningococcal Vaccines; D018074:Vaccines, Conjugate